GC1008

BIOLOGICAL4 trials

Sponsors

Genzyme, a Sanofi Company, Abramson Cancer Center at Penn Medicine, University Medical Center Groningen

Conditions

Focal Segmental GlomerulosclerosisIdiopathic Pulmonary FibrosisPleural Malignant MesotheliomaPrimary Brain Tumors

Phase 1

Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT00125385

Genzyme, a Sanofi CompanyIdiopathic Pulmonary Fibrosis

Start: 2005-07-31End: 2008-09-30Updated: 2015-04-13

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

CompletedNCT00464321

Genzyme, a Sanofi CompanyFocal Segmental Glomerulosclerosis

Start: 2007-05-31End: 2010-02-28Updated: 2014-03-19

Phase 2

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

CompletedNCT01112293

Abramson Cancer Center at Penn MedicinePleural Malignant Mesothelioma

Start: 2010-04-30End: 2014-12-31Updated: 2020-04-10

Safety and Imaging Study of GC1008 in Glioma

CompletedNCT01472731

University Medical Center GroningenPrimary Brain Tumors

Start: 2011-12-31End: 2012-11-30Updated: 2024-05-06

Related Papers

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations